ADELAIDE, Australia / RankWire.AI / – Researchers in Australia have pinpointed a molecular switch responsible for controlling the dissemination of aggressive tumors, revealing a potential therapeutic route to prevent secondary cancers. The study, published in EMBO Molecular Medicine, involved scientists from Adelaide University and the Olivia Newton-John Cancer Research Institute, who showed that restoring the levels of a crucial regulatory molecule known as miR-342 considerably diminishes tumor spread. These results propose a new promising approach to managing triple-negative breast cancer by targeting dormant cancer cells before they develop into life-threatening secondary lesions in distant organs.
Although triple-negative breast cancer represents 10% to 15% of Australia’s roughly 21,000 annual breast cancer diagnoses, it accounts for a disproportionate share of mortality because this subtype lacks estrogen, progesterone, and HER2 receptors, which renders standard hormone-targeted therapies ineffective. The research team demonstrated that when miR-342 expression drops, it results in overactivation of a cancer-promoting pathway called E2F, enabling dormant cancer cells to disseminate throughout the body and give rise to dangerous secondary tumors.
Targeted Treatments Bring New Hope for Preventing High-Risk Metastasis
In preclinical experiments, scientists found that increasing miR-342 levels significantly hindered the spread of cancer cells to distant sites. Additionally, they identified that palbociclib, an existing CDK4/6 inhibitor currently approved for hormone receptor-positive breast cancers, notably stopped metastatic tumor growth in models with low miR-342 levels. These findings imply that measuring miR-342 could enable physicians to repurpose existing drugs for treating patients at high risk of metastasis.
Associate Professor Philip Gregory from Adelaide University’s Centre for Cancer Biology, who served as co-senior author, confirmed that the primary obstacle in treating aggressive breast cancers remains metastasis prevention. Gregory emphasized that because palbociclib targets the hyperactive E2F pathway, administering the drug after cancer cells have disseminated prevents the growth of microscopic deposits. This approach shifts the focus from merely shrinking primary tumors to stopping microscopic secondary cancers from progressing into lethal conditions.
Pre-Clinical Data Published in Peer-Reviewed EMBO Molecular Medicine
The research team highlighted that the biological diversity of triple-negative breast cancer has historically impeded the development of universal targeted therapies. By identifying a specific biological vulnerability shared by a particular patient subgroup, the study paves the way for personalized treatment strategies. As Australian scientists explore a promising new method to combat triple-negative breast cancer, teams are preparing to validate these findings using patient-derived models prior to clinical trial phases.
Cancer specialists and research organizations across Australia expressed their support for the study, emphasizing the urgent need for expanded treatment options when primary therapies are insufficient. The research team intends to work with international clinical networks to speed up biomarker screening procedures. Confirming the efficacy of miR-342 testing could soon enable clinicians to identify suitable candidates for targeted CDK4/6 inhibitor therapies early in the treatment process.